Antiviral Activity of a Llama-Derived Single-Domain Antibody against Enterovirus A71

Peng-Nien Huang, Hsiang-Ching Wang, Hui-Chen Hung, Sung-Nien Tseng, Teng-Yuan Chang, Min-Yuan Chou, Yu-Jen Chen, Yun-Ming Wang, Shin-Ru Shih, John Tsu-An Hsu*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

In the past few decades, enterovirus A71 (EVA71) has caused devastating outbreaks in the Asia-Pacific region, resulting in serious sequelae in infected young children. No preventive or therapeutic interventions are currently available for curing EVA71 infection, highlighting a great unmet medical need for this disease. Here, we showed that one novel single-domain antibody (sdAb), F1, isolated from an immunized llama, could alleviate EVA71 infection both in vitro and in vivo. We also confirmed that the sdAb clone F1 recognizes EVA71 through a novel conformational epitope comprising the highly conserved region of VP3 capsid protein by using competitive-binding and overlapping-peptide enzyme-linked immunosorbent assays (ELISAs). Because of the virion's icosahedral structure, we reasoned that adjacent epitopes must be clustered within molecular ranges that may be simultaneously bound by an engineered antibody with multiple valency. Therefore, two singledomain binding modules (F1) were fused to generate an sdAb-in-tandem design so that the capture of viral antigens could be further increased by valency effects. We showed that the tetravalent construct F1xF1-hFc, containing two sdAb-intandem on a fragment crystallizable (Fc) scaffold, exhibits more potent neutralization activity against EVA71 than does the bivalent sdAb F1-hFc by at least 5.8-fold. We also demonstrated that, using a human scavenger receptor class B member 2 (hSCARB2) transgenic mouse model, a half dose of the F1xF1-hFc provided better protection against EVA71 infection than did the F1-hFc. Thus, our study furnishes important insights into multivalent sdAb engineering against viral infection and provides a novel strategic deployment approach for preparedness of emerging infectious diseases such as EVA71.

Original languageEnglish
Article numberARTN e01922-19
Number of pages17
JournalAntimicrobial Agents and Chemotherapy
Volume64
Issue number5
DOIs
StatePublished - May 2020

Keywords

  • antiviral research
  • enterovirus A71
  • hSCARB2 transgenic mice
  • single-domain antibody
  • MONOCLONAL-ANTIBODY
  • NEUTRALIZING ACTIVITY
  • 71 INFECTION
  • IN-VIVO
  • EPITOPE
  • NANOBODY
  • VP3
  • IDENTIFICATION
  • GENERATION
  • DISEASE

Cite this